Controlling angiogenesis in vivo is strongly being considered by pathologists and experimenters due to the recent success of using anti-angiogenic therapy for cancer patients in clinical trials. The apparent nature and overwhelming number of cases of lung cancer (bronchogenic carcinoma) are leading some clinicians to using anti-angiogenic pharmaceuticals with lung-cancer patients. Pre-clinical and experimental evidence supporting the use of anti-angiogenic therapy for lung cancer is apparently increasing. The literature research here attempts to point out specific relationships between lung tumor growth and the mechanisms by which the body reacts to such. Macrophages, lymphocytes, fibroblasts, vascular smooth muscle cells, lung alveolar, and vascular endothelial cells all play roles in such wound-healing mechanisms as inflammation, angiogenesis, and fibrogenesis that involve growth factors and that are activated in the presence of an invasive lung neoplasm. Elaboration on many of these cell-extracellular matrix interactions of normal and tumorous tissues might lead to a better understanding and a stronger foundation for being able to utilize or derive a highly accurate antiangiogenic therapy for one of the largest causes of cancer-related mortality.
Diseases | Medical Sciences | Medicine and Health Sciences
Middleton, Peter Alan, "An Exploration of Possibly Using Anti-Angiogenic Therapy as a Treatment for Lung Cancer" (1998). Honors College Capstone Experience/Thesis Projects. Paper 133.